Cryoport, Inc. (NASDAQ:CYRX) Short Interest Down 5.5% in January

Cryoport, Inc. (NASDAQ:CYRX) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 2,080,000 shares, a decrease of 5.5% from the December 31st total of 2,200,000 shares. Based on an average trading volume of 405,400 shares, the days-to-cover ratio is currently 5.1 days. Approximately 4.4% of the company’s stock are sold short.

Analyst Ratings Changes

CYRX has been the subject of a number of analyst reports. Roth Mkm decreased their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research note on Friday, January 17th. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, UBS Group increased their price target on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Cryoport has an average rating of “Moderate Buy” and an average price target of $12.29.

Cryoport Stock Performance

Cryoport stock traded down $0.16 during mid-day trading on Monday, hitting $7.38. 268,881 shares of the company’s stock traded hands, compared to its average volume of 272,142. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The firm has a 50 day simple moving average of $7.85 and a two-hundred day simple moving average of $7.95. Cryoport has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The stock has a market cap of $364.79 million, a price-to-earnings ratio of -2.18 and a beta of 1.59.

Cryoport (NASDAQ:CYRX) last announced its earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.23. The business had revenue of $56.66 million during the quarter, compared to the consensus estimate of $58.13 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the previous year, the firm posted ($0.31) EPS. On average, research analysts expect that Cryoport will post -0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the transaction, the director now owns 59,497 shares in the company, valued at approximately $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $6.51, for a total transaction of $325,500.00. Following the completion of the transaction, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,869 shares of company stock valued at $735,673 in the last quarter. 10.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cryoport

Several institutional investors and hedge funds have recently made changes to their positions in CYRX. Thematics Asset Management boosted its holdings in Cryoport by 176.2% in the 3rd quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock valued at $13,828,000 after purchasing an additional 1,087,800 shares during the period. Fred Alger Management LLC raised its position in shares of Cryoport by 49.9% in the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock valued at $21,887,000 after buying an additional 898,481 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Cryoport in the third quarter valued at approximately $3,405,000. JPMorgan Chase & Co. grew its position in Cryoport by 1,464.4% during the third quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company’s stock worth $2,475,000 after buying an additional 285,726 shares in the last quarter. Finally, Algert Global LLC grew its position in Cryoport by 282.7% during the third quarter. Algert Global LLC now owns 247,483 shares of the company’s stock worth $2,007,000 after buying an additional 182,808 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.